Disease · MONDO_0016486
Trials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
1 to 20 of 20
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00390858 | A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. | Phase 2 | 40 | 2011-08-15 | Transfusional Iron Overload, β-thalassemia Major, Pediatric Rare Anemia | DEFERASIROX | Its record names the disease | ClinicalTrials.gov |
| NCT02435901 | HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity | Phase 1/2 | 29 | 2020-11-05 | Sickle Cell Disease, Beta Thalassemia-Major | ALEMTUZUMAB, CYCLOSPORINE, FLUDARABINE, MELPHALAN, MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS | Its record names the disease | ClinicalTrials.gov |
| NCT06468423 | Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload | Not applicable | 142 | Pateints of β-thalassemia Major With Iron Overload | DEFERASIROX, DEFEROXAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00999349 | Therapeutic Effects of Silymarin in Patients With B-thalassemia Major | Phase 2/3 | 140 | Beta-thalassemia Major, Iron Overload | SILYMARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04260516 | The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major | Phase 1 | 100 | Thalassemia Major | ACETYLCYSTEINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT07292259 | Combination of Thalidomide and Hydroxyuria in Transfusion Dependent Thalasemmia | Phase 2 | 100 | Transfusion Dependent Beta Thalassemia | HYDROXYUREA, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT07338344 | Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients | Phase 2 | 78 | Transfusion-dependent β-thalassemia Patients | LUSPATERCEPT, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT02173951 | An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients | Phase 2/3 | 64 | Beta Thalassemia Major | DEFERIPRONE | Its record names the disease | ClinicalTrials.gov | |
| NCT06596642 | A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan | 61 | β-Thalassemia Major | LUSPATERCEPT | Its record names the disease | ClinicalTrials.gov | ||
| NCT01511848 | Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload | Phase 2/3 | 60 | Beta-thalassemia Major, Sickle Cell Disease, Iron Hemosiderosis | DEFERASIROX, DEFERIPRONE, DEFEROXAMINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02761395 | Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major | Not applicable | 60 | AL-Hijama in Thalassmia Major | DEFERASIROX | Its record names the disease | ClinicalTrials.gov | |
| NCT02671695 | Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia | Not applicable | 40 | Beta Thalassemia Major | AMLODIPINE | Its record names the disease | ClinicalTrials.gov | |
| NCT03948737 | The Effect of Alpha-tocopherol in Hemolysis and Oxidative Stress Marker on the Red Cell Membrane Beta-thalassemia Major | Not applicable | 40 | Beta Thalassemia Major Anemia, Hemolysis, Oxidative Stress | ALPHA-TOCOPHEROL | Its record names the disease | ClinicalTrials.gov | |
| NCT00336362 | Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major | Not applicable | 26 | Beta-Thalassemia | HYDROXYUREA | Its record names the disease | ClinicalTrials.gov | |
| NCT01752153 | Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major | Phase 1 | 25 | Immune Abnormalities | DEFEROXAMINE, SILYMARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04353986 | PK of SOF/LED in HCV - Infected Adolescents With Haematological Disorders | Phase 3 | 24 | HCV Infection, Beta Thalassemia Major | LEDIPASVIR, SOFOSBUVIR | Its record names the disease | ClinicalTrials.gov | |
| NCT01206075 | Evaluating the Safety and Effectiveness of Mozobil Mobilization in Adults With Beta-Thalassemia Major | Not applicable | 20 | Beta-Thalassemia | PLERIXAFOR | Its record names the disease | ClinicalTrials.gov | |
| NCT04092205 | Phase 2a Pilot Study of NBMI Treatment in Patients With Beta Thalassemia Major, Requiring Iron Chelation | Phase 2 | 13 | Beta Thalassemia Major | EMERAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01125254 | Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major | Phase 2/3 | 10 | Thalassemia Major | AMLODIPINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03653338 | T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias | Phase 1/2 | 5 | Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan Anemia | ALEMTUZUMAB, FLUDARABINE, HYDROXYUREA, RITUXIMAB, THIOTEPA | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016486/trials